Log In
Print
BCIQ
Print
Print this Print this
 

Rozerem, ramelteon (TAK-375)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionMelatonin MT1 and MT2 receptors agonist
Molecular Target Melatonin MT1 receptor ; Melatonin MT2 receptor
Mechanism of ActionMelatonin MT2 receptor agonist; Melatonin MT1 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat chronic insomnia; Treat chronic transient insomnia; Treat circadian rhythm sleep disorder; Treat insomnia; Treat primary insomnia; Treat transient insomnia
Regulatory Designation
Partner Meiji Seika Pharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today